The Patient-Centric Approach in Health Economics

By Staff Writer

January 24, 2024

A Paradigm Shift in Health Economics and Outcomes Research

HEOR, which refers to health economics and outcomes research, is a realm that is difficult to navigate due to its complexity, diverse nature, and numerous facets. Nevertheless, there is one key element that stands out: the patient is the most important element. With the purpose of shedding light on the influence that this trend has on healthcare systems around the world, this article investigates the increased emphasis on a patient-centric approach in HEOR.

The Core of Health and Education

At its core, HEOR is a multidisciplinary field that aims to enhance the accessibility, fairness, and efficiency of healthcare systems for patients. It requires an understanding and appreciation of factors that significantly affect patients’ health and their experiences. This field prioritises what truly matters to patients.

The Importance of ISPOR in the Support of Patient-Centred Patient Care

Rob Abbott, as the CEO and Executive Director of The International Society for Pharmacoeconomics and Outcomes Research (ISPOR), emphasised the importance of encouraging patient-focused work. He defined this as a collaborative and meaningful interaction between patients and researchers, occurring throughout the entire research process. During the decision-making process, patient experiences, values, and expertise serve as guiding principles. This helps to ensure that the data collected ultimately contributes to the improvement of patient outcomes.

Progress and Obstacles

Significant progress has been made in centering patients in HEOR, but much work remains. We need to boost the patient’s voice and create a more patient-focused decision-making process. However, integrating the patient throughout the entire healthcare journey presents significant challenges. 

Regarding the Future Strategy of ISPOR and the Function of HEOR

As ISPOR moves on with a new plan for the year 2024, it is making concerted efforts to establish HEOR as a crucial instrument for addressing the most significant challenges in the field of global healthcare. Affordability, the impact of the rapid digitalisation of health care, and the increased desire in providing comprehensive health care are some of these factors. The patient, on the other hand, is the focal point of each and every one of these issues.

Concluding remarks

When it comes to HEOR, the patient-centric approach focuses not only on improving people’s health but also on improving the patient experience in situations where their health has been compromised. In this context, it refers to making sure that the patients’ voices are heard and that their requirements are addressed.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.